BIO KOREA 2026 is fast approaching, taking place in Seoul next month and once again bringing together leading global stakeholders in biotechnology, pharmaceuticals, medical technology, and research. As one of the most established life‑science events in Asia, it provides a dynamic platform for partnership building, scientific exchange, and showcasing innovations that drive the future of healthcare.
SyVento BioTech will be joining this year’s international community of innovators. Throughout the event, Andreas Stocker, Commercial Advisor, will represent the company in discussions with partners and industry leaders.
BIO Korea’s focus on next‑generation therapeutic technologies aligns closely with SyVento BioTech’s integrated offering. Our capabilities include comprehensive end‑to‑end CDMO services for RNA‑based therapeutics, advanced LNP formulation development, as well as GMP manufacturing and fill & finish of injectable drug products to support both clinical and commercial readiness.
We look forward to productive conversations in Seoul and to presenting how SyVento BioTech helps transform breakthrough scientific concepts into safe, scalable, and effective therapeutic products.
